{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Carvalho AM"],"funding":["Horizon 2020 Framework Programme","Children&apos;s Cancer and Leukaemia Group"],"pagination":["6503-6514"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11480974"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(10)"],"pubmed_abstract":["Paediatric acute myeloid leukemia (AML) is a heterogeneous hematological malignancy still heavily reliant on traditional chemotherapeutic approaches. Combination treatments have shown to be a superior approach, but their success is often hindered by side effects and different drugs' pharmacokinetics. Here, we investigated ABT-737 and Purvalanol A as a potential drug pairing for pediatric AML and described the development of CD33-targeted polymeric nanoparticles (NPs) to enable their simultaneous targeted codelivery. Separate drug encapsulation within poly(lactic-<i>co</i>-glycolic acid) (PLGA) NPs was optimized prior to coencapsulation of both drugs at a synergistic ratio in PEGylated PLGA NPs. The therapeutic effects of formulations were evaluated in a panel of pediatric AML cells, and du"],"journal":["Biomacromolecules"],"pubmed_title":["Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia."],"pmcid":["PMC11480974"],"funding_grant_id":["CCLGA 2019 01","859458"],"pubmed_authors":["Greene MK","Scott CJ","Smyth P","Mutch A","Cairns LV","Mills KI","McLaughlin KM","McCloskey KD","Carvalho AM"],"additional_accession":[]},"is_claimable":false,"name":"Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia.","description":"Paediatric acute myeloid leukemia (AML) is a heterogeneous hematological malignancy still heavily reliant on traditional chemotherapeutic approaches. Combination treatments have shown to be a superior approach, but their success is often hindered by side effects and different drugs' pharmacokinetics. Here, we investigated ABT-737 and Purvalanol A as a potential drug pairing for pediatric AML and described the development of CD33-targeted polymeric nanoparticles (NPs) to enable their simultaneous targeted codelivery. Separate drug encapsulation within poly(lactic-<i>co</i>-glycolic acid) (PLGA) NPs was optimized prior to coencapsulation of both drugs at a synergistic ratio in PEGylated PLGA NPs. The therapeutic effects of formulations were evaluated in a panel of pediatric AML cells, and du","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2025-04-04T07:40:42.467Z","creation":"2025-04-04T07:40:42.467Z"},"accession":"S-EPMC11480974","cross_references":{"pubmed":["39235263"],"doi":["10.1021/acs.biomac.4c00672"]}}